Highly active antiretroviral therapy

Biological products industry

Predictors of Discontinuing Injectable Cabotegravir/Rilpivirine and Virologic Outcomes After Resuming Oral Antiretroviral Therapy

Researchers at the University of California have conducted a retrospective cohort study to evaluate factors associated with discontinuation of long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART). The study found that individuals with substance use demonstrated a higher